Company Performance Metrics
- Jonathan Lane: Co-Founder and General ManagerPast Role: Nanogenic Solutions, Director Business Development
Nanogenic Solutions operates as a company developing the artificial virus, a new kind of vector for gene therapy. Nanogenic Solutions have committed to overcoming the obstacle of delivery to fulfil the promise of gene therapy, working alongside innovative partners to bring cutting-edge treatments to market. Nanogenics is developing LipTide, an
artificial virus, which acts as a custom-built delivery system that can be modified to target different cell types and deliver different payloads, making the promise of gene therapy one step closer to reality. LipTide is a protein based nanoparticle, which mimics natural viruses, but by-passes the many problems of viral delivery. The ability to regularly dose gene therapy payloads with LipTide could revolutionise the approach to gene therapy
